Part ofhealthcare →

S4426FEDERALIN_COMMITTEE

High Impact

Promising Pathway Act 2.0: New Conditional Approval Process for Rare Disease Drugs

Original title: Promising Pathway Act 2.0

May 23, 2024

healthcare drug-approval rare-diseases fda insurance-coverage

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Where This Stands

Introduced

Committee

Floor Vote

Passed

Signed

Currently IN_COMMITTEE. The next step in the legislative lifecycle is Floor Vote.

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

The Frame

What this does

If passed, this bill would allow patients with rare or terminal conditions to access certain drugs before full FDA approval, while requiring insurers to cover the full cost of these treatments.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Patients with rare or serious diseases

Patients gain access to conditionally approved drugs and are required to enroll in observational registries to receive them.

Health insurance issuers

Insurers are required to provide coverage for these drugs without cost-sharing for patients.

Drug sponsors

Sponsors must establish observational registries, submit data to the FDA, and adhere to strict labeling and marketing requirements.

What changed

Current stage: IN_COMMITTEE.

What's next

Floor Vote.

Summary

This bill creates a new, time-limited '' pathway for drugs intended to treat serious, rare, or rapidly progressive diseases. It requires patients taking these drugs to enroll in observational registries to track safety and effectiveness, and mandates that health insurance plans cover these drugs without for patients.

Why It Matters

If passed, this bill would allow patients with rare or terminal conditions to access certain drugs before full FDA approval, while requiring insurers to cover the full cost of these treatments.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

Will my insurance cover these drugs?

Yes, the bill requires both private health insurance plans and federal health care programs to cover these drugs without imposing any requirements on the patient.

What happens if the FDA withdraws approval for a drug I am taking?

If approval is withdrawn, the sponsor cannot provide the drug to new patients, but patients already taking the drug may continue to do so if they choose.

Do I have to participate in a study to get these drugs?

Yes, patients must enroll in an to track their health outcomes as a condition of receiving the drug.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Shift toward Real-World Evidence

The bill explicitly mandates the use of real-world evidence and observational registries as a core component of the drug approval and renewal process, signaling a move away from relying solely on traditional clinical trials.

Food and Drug Administration

Connected Entities

personBooker“Senator Booker was a co-sponsor of the bill.”Map →

organizationSecretary“The Secretary of the Food and Drug Administration (FDA).”Map →

personSchmitt“Senator Schmitt was a co-sponsor of the bill.”Map →

personPadilla“Senator Padilla was a co-sponsor of the bill.”Map →

personHawley“Senator Hawley was a co-sponsor of the bill.”Map →

organizationHomeland Security“The Department of Homeland Security.”Map →

personGillibrand“Senator Gillibrand was a co-sponsor of the bill.”Map →

personVance“Senator Vance was a co-sponsor of the bill.”Map →

personCramer“Senator Cramer was a co-sponsor of the bill.”Map →

personManchin“Senator Manchin was a co-sponsor of the bill.”Map →

personBraun“Senator Braun was the lead sponsor of the bill.”Map →

personWelch“Senator Welch was a co-sponsor of the bill.”Map →

organizationSenate“The bill was introduced by a group of Senators.”Map →

personMurkowski“Senator Murkowski was a co-sponsor of the bill.”Map →

Analysis Score

0–100

Significance85
How much this matters to a regular citizen
Controversy40
Intensity of disagreement among stakeholders
Entertainment10
Compellingness for a non-policy-wonk reader
Buzz25
Current news / social attention level

Publisher tools